Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

The global anti-osteoporosis therapy and fracture healing market is poised for remarkable growth, with projections indicating a rise from USD 14,051.6 million in 2023 to USD 22,427.6 million by 2033, ...

This report highlights major developments in the health sector, including WeightWatchers offering a new obesity drug, Danco ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...